Viking Therapeutics' VK2735 Maintains Weight Loss With Less Frequent Dosing; VKTX Rises

Viking Therapeutics Inc. (VKTX) reported positive topline results from a maintenance study of its obesity drug candidate VK2735 on Sept. 22, 2026, showing patients sustained most of their prior weight loss after transitioning from weekly dosing to less frequent administration. The company's shares rose on the news. The mid-stage data support a potential dosing advantage for VK2735 in the competitive obesity treatment market, where less frequent injections could improve patient adherence. Specific efficacy figures and the exact dosing intervals were not disclosed in the initial release. Viking is among several developers targeting the expanding GLP-1 weight-loss sector. The company said it plans to advance VK2735 into further clinical testing.